Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

IMI (International Medical Innovations) begins trial of early cancer markers

This article was originally published in Clinica

  • News

Executive Summary

Canadian company International Medical Innovations (IMI) has begun trials of two new screening tests for early diagnosis of colorectal cancer, the third most common cancer in North America. It is the first large trial of the tests, known as CA1-18 and RMT, says Dr Norman Marcon, a gastroenterologist at St Michael's Hospital Toronto, where the 600-patient study is being carried out.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

ORA’s Chief Says Without Additional Funding, Inspections Are In Jeopardy

News We’re Watching: Philips Settles Recall Fallout; FDA REdI, Townhalls, Approvals

ICER Debuts Clinical Trial Diversity Assessment Framework

UK MHRA’s Strategic Approach To AI Will Be ‘Proportionate’ And Fit Well Internationally

See All
UsernamePublicRestriction

Register

MT077220

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By